CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.75BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.6850xvs all stocks
52-Week Change
18.85%vs all stocks
Market Capitalization
3.75BUSDvs all stocks (USD)
Enterprise Value
3.45BUSDvs all stocks (USD)
Forward P/E
-7.84xvs Biotechnology peers
Price to Book (MRQ)
9.67xvs Biotechnology peers
Enterprise to EBITDA
-8.79xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-51.86%vs Biotechnology peers
Return on Equity (TTM)
-88.85%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Aug 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-534.80MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-418.44MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-230.79MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-393.34MUSDvs all stocks (USD)
Pre-tax Income
-359.64MUSDFY2025 · Dec 31, 2025Net Income
-359.64MUSDFY2025 · Dec 31, 2025EBIT
-393.34MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-392.97MUSDFY2025 · Dec 31, 2025Research & Development
344.95MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
48.39MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
33.70MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.19USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.19USDFY2025 · Dec 31, 2025Basic Shares Outstanding
112.67MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
112.67MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-359.64MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-270.31MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
165.81MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-359.64MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
431.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
40.82MUSDFY2025 · Dec 31, 2025Other Non-cash Items
66.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
5.08MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
43.44MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-505.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-418.04MUSDFY2025 · Dec 31, 2025Sale of Investments
759.42MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
341.39MUSDFY2025 · Dec 31, 2025Other Financing Charges
73.95MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
73.95MUSDFY2025 · Dec 31, 2025Shares Outstanding
116.65MSharesUpdated Aug 28, 2026Float Shares
113.73MSharesUpdated Aug 28, 2026Shares Short
22.29MSharesUpdated Aug 28, 2026Short Ratio
11.73daysvs all stocks
Short % of Shares Outstanding
20.19%vs all stocks
% Held by Insiders
3.09%vs all stocks
% Held by Institutions
66.12%vs all stocks
Total Cash (MRQ)
501.66MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.30USDUpdated Aug 28, 2026Total Debt (MRQ)
4.09MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0100xvs Biotechnology peers
Current Ratio (MRQ)
4.72xvs Biotechnology peers
Book Value per Share (MRQ)
3.50USDUpdated Aug 28, 2026Total Assets
715.73MUSDvs all stocks (USD)
Total Current Assets
715.60MUSDFY2025 · Dec 31, 2025Total Liabilities
76.67MUSDFY2025 · Dec 31, 2025Total Non-current Assets
131.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
76.67MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
165.81MUSDFY2025 · Dec 31, 2025Other Short-term Investments
539.93MUSDFY2025 · Dec 31, 2025Accounts Payable
53.25MUSDFY2025 · Dec 31, 2025Short-term Debt
137.00KUSDFY2025 · Dec 31, 2025Long-term Debt
0.00USDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-847.55MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
639.06MUSDvs all stocks (USD)
Treasury Stock
0.00USDFY2025 · Dec 31, 202552-Week Low
22.96USDUpdated Aug 28, 202652-Week High
43.15USDUpdated Aug 28, 202652-Week Change
18.85%vs all stocks
Beta
0.6850xvs all stocks
50-Day MA
35.46USDUpdated Aug 28, 2026200-Day MA
33.67USDUpdated Aug 28, 2026Avg 10-Day Volume
1.69MSharesUpdated Aug 28, 2026Avg 30-Day Volume
1.91MSharesUpdated Aug 28, 2026Diluted EPS (TTM)
-4.60USDUpdated Aug 28, 2026Other Income / Expense
55.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.62
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 32,166,921.735
Levered free cash flow is -$230.79M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -230,792,128Global P5: -209,187,555.994
Market cap is $3.75B, above the global median of $1.18BNotable
Market cap (USD): 3,749,808,659Global Median: 1,179,398,897.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Iovance Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Tiantan Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ambu A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Grand Pharmaceutical and Healthcare Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Irhythm Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Apeloa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Arcus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Catalyst Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Huahai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Zhejiang Hisun Biomaterials Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
HBL Engineering Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Olaplex Holdings, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity